• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » PAD: Intact Vascular touts 1st-in-human results

PAD: Intact Vascular touts 1st-in-human results

May 7, 2015 By Mark Hollmer

Intact Vascular touts 1st-in-human results

Intact Vascular said a 1st-in-human study of a device designed to repair arterial dissections after angioplasty has produced encouraging results.

Details of the safety and feasibility study involving 11 patients were published in the Journal of the American College of Cardiology: Cardiovascular Interventions, along with supporting preclinical data.

Testing revolved around the Pennsylvania company’s Tack endovascular system, which is designed to use a minimal metal implant to repair post-angioplasty arterial dissections, an innovation over current treatment standards thought to reduce vessel trauma and inflammation. The 11 patients had 25 treated lesions between them, and the study took place at 2 Paraguay hospitals.

Researchers looked at the patients post-procedure and after 12 months. They found surgeons achieved a 100% repair level of dissection flaps. At 1 year, there was an 87.5% patency rate for superficial femoral artery and popliteal vessels, and an 83.3% patency rate for superficial femoral artery, popliteal and tibial artery vessels treated.

For patients who just had tibial vessels treated, there was an 80% patency rate, according to the study.

No patient lost a limb or had their implant migrate. Researchers noted 1 target legion revascularization and death occurred, but it was not related to the device or procedure.

Intact Vascular president & CEO Bruce Shook said the data, combined with recently presented 12-month European TOBA clinical trial data, give the company a good impetus to proceed.

Both, Shook said in prepared remarks, "make for a strong foundation as we move forward."

Shook took over the corner office at Intact Vascular last July. He is the co-founder and former CEO of Neuronetics and the ex-president of Abiomed (NSDQ:ABMD).

Filed Under: News Well Tagged With: Clinical Trials, Intact Vascular, Peripheral

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy